Form 4: Recursion Pharma CSO Hallett Reports Tax-Related Stock Transaction

Recursion Pharmaceuticals' Chief Scientific Officer, David Hallett, reported a tax-related disposition of 11,908 Class A Common Stock shares.

Summary

• David Hallett, Chief Scientific Officer of Recursion Pharmaceuticals, Inc. (RXRX), reported a transaction on February 17, 2026.
• The transaction involved the disposition of 11,908 shares of Class A Common Stock.
• These shares were withheld by the company to cover tax withholding and remittance obligations related to the net settlement of restricted stock units.
• The deemed price for these shares was $3.49 per share.
• Following this transaction, David Hallett directly beneficially owns 1,097,151 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. While it represents a reduction in shares, it's a non-discretionary tax withholding, not a sale indicating a lack of confidence.

Positives

• The transaction is a non-discretionary tax withholding event, not a sale indicating a lack of confidence by the insider.
• David Hallett continues to hold a substantial number of shares (1,097,151) in the company.

Negatives

• The number of shares beneficially owned by the Chief Scientific Officer decreased by 11,908 due to tax withholding.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that routine Form 4 filings for tax-related dispositions of restricted stock units are common for executives and typically do not indicate a change in management's confidence or a strategic shift, but rather a standard compensation and tax event.

Comparison to Industry Standards

• This is a standard tax withholding transaction common across industries for executives receiving equity compensation.
• It aligns with typical practices for managing RSU vesting and associated tax liabilities, similar to what is observed in other biotechnology and pharmaceutical companies.

Stakeholder Impact

• Shareholders might observe a minor reduction in direct insider ownership, but the nature of the transaction (tax withholding) suggests minimal impact on the perception of company health or management confidence.

Key Dates

Recommendation

This Form 4 filing details a routine tax-related disposition of shares by a Chief Scientific Officer, which is a common occurrence with restricted stock unit vesting. It does not reflect a discretionary sale or provide new information about the company's operational or financial performance. Therefore, it offers no basis to change an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Recursion Pharmaceuticals, RXRX, David Hallett, Form 4, Insider Transaction, Stock Ownership, Restricted Stock Units, Tax Withholding, Chief Scientific Officer